Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2021

View Archived Issues

Merck & Co. identifies compounds for treating herpes virus infection

Nuclear receptor ROR-gamma modulators discovered at Nuevolution

ARKUDA Therapeutics describes new progranulin modulators

AbbVie, Calico Life Sciences patent PROTACs targeting PTPN1 and/or PTPN2

Guangdong Feipeng Pharmaceutical presents anti-PD-1 antibodies

Nascent and Manhattan BioSolutions present preliminary data for BCG-based COVID-19 vaccine

Serum miR-146a is elevated in patients with COVID-19

FDA accepts IND application for phase I/II study of ExoFlo in ARDS

Blue Water Vaccines licenses novel VLP vaccine platform from Cincinnati Children's

GLPG-3970 shows clinical activity in early phase clinical trials

Positive topline data from phase Ib study of GLPG-3667 in psoriasis

Serum HBD2 is a marker of chronic spontaneous urticaria

First patient dosed in global phase I study of TST-005

Tumor suppressor p53 is inactivated by lncRNA

Novel PIV5-based mucosal vaccine protects mice and ferrets against SARS-CoV-2 challenge

IL-1alpha inhibition reduces hyperinflammation in a COVID-19 murine model

H3Mab-17 significantly reduces tumor growth in mouse model of colorectal adenocarcinoma

KRIBB-11 controls molecular pathways with potential for therapeutic strategy for glioblastoma

Phase II trial evaluates combination of VIR-2218 and VIR-3434 for chronic hepatitis B

BetterLife's AP-003 shows in vitro antiviral activity against SARS-CoV-2

Dosing underway in phase I study of IBI-319 in advanced malignant tumors

Compugen studies COM-902 in combination with COM-701 for advanced malignancies in phase I

Synlogic begins phase I study of SYNB-1934 for phenylketonuria

NCCN announces funded research projects to evaluate neratinib in cancer

Covimro shows in vivo efficacy in murine model of influenza A H3N2 infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...